Evidence map›Paper›PMID 41439963›Full record

ArticleCells2025

Elena Ekrami, Parisa Ghanbari, Eman M Othman, Aladar A Szalay

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elena EkramiCancer Therapy Research Center (CTRC), Department of Biochemistry-I, Biocenter, University of Würzburg, 97074 Würzburg, Germany.ORCID 0000-0003-2343-4250
Parisa GhanbariCancer Therapy Research Center (CTRC), Department of Biochemistry-I, Biocenter, University of Würzburg, 97074 Würzburg, Germany.
Eman M OthmanCancer Therapy Research Center (CTRC), Department of Biochemistry-I, Biocenter, University of Würzburg, 97074 Würzburg, Germany.ORCID 0000-0003-4781-9745
Aladar A SzalayCancer Therapy Research Center (CTRC), Department of Biochemistry-I, Biocenter, University of Würzburg, 97074 Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma and neuroblastoma are aggressive brain and pediatric tumors with limited treatment options.

methodsWe developed an in vitro co-culture model using mouse microglia (BV2) infected with VV (LIVP strain) to deliver the virus to glioblastoma (U87) and neuroblastoma (SH-SY5Y) cells in both 2D and 3D systems. Our results demonstrated that VV-infected Microglia can efficiently deliver the virus to tumor cells, inducing substantial cytotoxic effects in both 2D and 3D models. Notably, the 3D cultures, which more closely mimic the native tumor microenvironment, exhibited the most pronounced enhancement in oncolysis.

conclusionsThis microglia-based delivery strategy enables potent oncolytic activity against brain tumor cells and warrants further exploration in in vivo and combinational therapies.

Indexed as

Brain NeoplasmsGlioblastomaMicrogliaNeuroblastomaOncolytic VirotherapyOncolytic VirusesVaccinia virusAnimalsCell Line, TumorCoculture TechniquesHumansMiceglioblastomamicroglianeuroblastomaoncolytic virotherapyvaccinia virus

Identifiers

PMID41439963
PMCPMC12730997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.